Ligand Pharma (LGND) Misses Q4 EPS by 45c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
- Goldman data shows hedge funds cut leverage at fastest pace since March
Tweet
Share
E-mailGet Alerts LGND Hot Sheet
Join SI Premium – FREE
Ligand Pharma (NASDAQ: LGND) reported Q4 EPS of $0.74, $0.45 worse than the analyst estimate of $1.19. Revenue for the quarter came in at $38.2 million versus the consensus estimate of $40.34 million.
GUIDANCE:
Ligand Pharma sees FY2017 EPS of $2.70.
For earnings history and earnings-related data on Ligand Pharma (LGND) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sotera Health Co. (SHC) Tops Q3 EPS by 2c; Offers Guidance
- Energy Transfer (ET) Misses Q3 EPS by 5c
- Regal Rexnord Corporation (RRX) Tops Q3 EPS by 25c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
